A practical reference on Cardarine: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-08-17. Anything still debated is marked as such rather than presented as settled.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
As this is a cube, the top and bottom surfaces are identical in shape and area, and the pressure difference between the top and bottom of the cube is directly proportional to the depth difference, and the resultant force difference is exactly equal to the weight of the fluid that would occupy the volume of the cube in its absence. This means that the resultant upward force on the cube is equal to the weight of the fluid that would fit into the volume of the cube, and the downward force on the cube is its weight, in the absence of external forces. This analogy is valid for variations in the size of the cube. If two cubes are placed alongside each other with a face of each in contact, the pressures and resultant forces on the sides or parts thereof in contact are balanced and may be disregarded, as the contact surfaces are equal in shape, size and pressure distribution, therefore the buoyancy of two cubes in contact is the sum of the buoyancies of each cube. This analogy can be extended to an arbitrary number of cubes. An object of any shape can be approximated as a group of cubes in contact with each other, and as the size of the cubes is decreased, the precision of the approximation increases. The limiting case for infinitely small cubes is the exact equivalence. Angled surfaces do not nullify the analogy as the resultant force can be split into orthogonal components and each dealt with in the same way.
== August 2013 interim report and governance charges == On 2 August 2013, almost seven months into the investigation, ASADA released an interim report to the AFL and Essendon Football Club. The interim report made no findings regarding the legality of the supplements program, but highlighted a wide range of governance and duty-of-care failures related to the program. On 13 August 2013, based on the interim report, AFL general counsel Andrew Dillon charged Essendon with "conduct that is unbecoming or likely to prejudice the interests or reputation of the Australian Football League or to bring the game of football into disrepute, contrary to AFL Rule 1.6". The charges included:
Stimulants, also known as "psychostimulants", induce euphoria with improvements in mental and physical function, such as enhanced alertness, wakefulness, and locomotion. Stimulants are also occasionally called "uppers". Depressants or "downers", which decrease mental or physical function, are in stark contrast to stimulants and are considered to be their functional opposites. Stimulants enhance the activity of the central and peripheral nervous systems. Common effects may include increased alertness, awareness, wakefulness, endurance, productivity, and motivation, arousal, locomotion, heart rate, and blood pressure, and a diminished desire for food and sleep. Use of stimulants may cause the body to significantly reduce its production of endogenous compounds that fulfill similar functions. Once the effect of the ingested stimulant has worn off the user may feel depressed, lethargic, confused, and dysphoric. This is colloquially termed a "crash" and may promote reuse of the stimulant. Amphetamines are a significant cause of drug-induced psychosis. Importantly, a 2019 meta-analysis found that 22% of people with amphetamine-induced psychosis transition to a later diagnosis of schizophrenia. Examples of stimulants include:
This is not a trivial difference; metabolomic studies should, by definition, exclude metabolic contributions from extragenomic sources, because these are external to the system being studied. However, in practice, within the field of human disease research there is still a large degree of overlap in the way both terms are used, and they are often in effect synonymous.
Ethacrynic acid is the only medication of this class that is not a sulfonamide. It carries a greater risk of reversible or permanent hearing loss (ototoxicity), and has a distinct complication of being associated with gastrointestinal toxicity.
Sources: en.wikipedia.org
=== sea-sef === Sea-Mist Seasonale Seba-Gel Sebcur sebetralstat (INN) Sebizon sebriplatin (INN) secalciferol (INN) secbutabarbital (INN) seclazone (INN) secnidazole (INN) secobarbital (INN) Seconal secoverine (INN) Secran Secreflo secretin (INN) Sectral secukinumab (INN) securinine (INN) Sedapap sedecamycin (INN) Seffin
With the goal of mitigating these disadvantages while applying nanotechnology to electronics, researchers at the National Science Foundation's Nanoscale Science and Engineering Center for High-Rate Nanomanufacturing (CHN) at Northeastern University with partners UMass Lowell and University of New Hampshire have developed a directed assembly process of single-walled carbon nano tube (SWNT) networks to create a circuit template that can be transfer from one substrate to another.
They are Silesia (Upper and Lower), Pomerania, West Prussia-Posen, and East Prussia respectively. Schaumburg-Lippe is now part of Lower Saxony. Württemberg is now part of Baden-Württemberg. Possible boundary changes between states continue to be debated in Germany, in contrast to how there are "significant differences among the American states and regional governments in other federations without serious calls for territorial changes" in those other countries. Arthur B. Gunlicks summarizes the main arguments for boundary reform in Germany: "the German system of dual federalism requires strong Länder that have the administrative and fiscal capacity to implement legislation and pay for it from own source revenues. Too many Länder also make coordination among them and with the federation more complicated." But several proposals have failed so far; territorial reform remains a controversial topic in German politics and public perception. A state capital is called a Landeshauptstadt.
==== Valvular heart disease ==== Diseased heart valves that have become abnormally narrow or abnormally leaky may require surgery. This is traditionally performed as an open surgical procedure to replace the damaged heart valve with a tissue or metallic prosthetic valve. In some circumstances, the tricuspid or mitral valves can be repaired surgically, avoiding the need for a valve replacement. Heart valves can also be treated percutaneously, using techniques that share many similarities with percutaneous coronary intervention. Transcatheter aortic valve replacement is increasingly used for patients considered to be at very high risk for open valve replacement.
Sources: en.wikipedia.org
Although a further tiny energy gain could be extracted by synthesizing 62Ni, which has a marginally higher binding energy than 56Fe, conditions in stars are unsuitable for this process. Element production in supernovas greatly favor iron over nickel, and in any case, 56Fe still has a lower mass per nucleon than 62Ni due to its higher fraction of lighter protons. Hence, elements heavier than iron require a supernova for their formation, involving rapid neutron capture by starting 56Fe nuclei. In the far future of the universe, assuming that proton decay does not occur, cold fusion occurring via quantum tunnelling would cause the light nuclei in ordinary matter to fuse into 56Fe nuclei. Fission and alpha-particle emission would then make heavy nuclei decay into iron, converting all stellar-mass objects to cold spheres of pure iron.
== Prognosis == No specific treatment is available. Management is only supportive and preventive. Those who are diagnosed with the disease often die within the first few months of life. Almost all children with the disease die by the age of three.
This phenomenon can be used in practical applications like LED's and solar cells. In these technologies either the efficiency of absorption or emission is of critical importance and nanoparticles with an interfacial layer could be used to improve this efficiency by either absorbing or emitting at a wider range of energies.
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.